EXICURE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
EXICURE, INC. (XCUR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2024-11-14
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.60.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.51, a 244.37% increase from fiscal 2021.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.60, a 119.18% increase from fiscal 2020.
- EXICURE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $0.73, a 16.09% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-06-17 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-06-06 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-05-16 | |||
| 2023-06-30 | $0.00 10-Q/A · filed 2024-06-06 | |||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-06 | |||
| 2022-12-31 | $5.51 10-K · filed 2024-06-06 | |||
| 2022-09-30 | $5.51 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $5.51 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | $1.60 10-K · filed 2022-03-25 | |||
| 2021-09-30 | $1.60 10-Q · filed 2021-11-19 | |||
| 2021-06-30 | $1.60 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $1.60 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $0.73 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $0.88 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.89 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $0.87 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $1.45 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $1.45 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $1.81 10-K/A · filed 2019-09-23 | |||
| 2018-09-30 | $1.81 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $0.86 10-Q · filed 2018-08-06 | |||
| 2018-03-31 | $0.86 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $0.75 10-K · filed 2018-03-09 | |||
| 2017-09-30 | $0.75 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |